These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28383355)

  • 1. Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients.
    Verboom MC; Visser L; Kouwen S; Swen JJ; Diepstraten J; Posthuma WF; Gelderblom H; van Lammeren D; Wilms EB
    Pharmacogenet Genomics; 2017 Jun; 27(6):223-226. PubMed ID: 28383355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.
    Barratt DT; Cox HK; Menelaou A; Yeung DT; White DL; Hughes TP; Somogyi AA
    Clin Pharmacokinet; 2017 Aug; 56(8):977-985. PubMed ID: 27995529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?
    Adehin A; Adeagbo BA; Kennedy MA; Bolaji OO; Olugbade TA; Bolarinwa RA; Durosinmi MA
    Leuk Lymphoma; 2019 Jan; 60(1):216-221. PubMed ID: 29741432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
    Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
    Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
    Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
    Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.
    Liu J; Chen Z; Chen H; Hou Y; Lu W; He J; Tong H; Zhou Y; Cai W
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
    Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.
    Ravegnini G; Sammarini G; Angelini S; Hrelia P
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):733-42. PubMed ID: 27149004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
    Gurney H; Wong M; Balleine RL; Rivory LP; McLachlan AJ; Hoskins JM; Wilcken N; Clarke CL; Mann GJ; Collins M; Delforce SE; Lynch K; Schran H
    Clin Pharmacol Ther; 2007 Jul; 82(1):33-40. PubMed ID: 17495881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients.
    Dalle Fratte C; Gagno S; Roncato R; Polesel J; Zanchetta M; Buzzo M; Posocco B; De Mattia E; Borsatti R; Puglisi F; Foltran L; Guardascione M; Buonadonna A; Cecchin E; Toffoli G
    Br J Clin Pharmacol; 2023 Mar; 89(3):1089-1098. PubMed ID: 36178950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib.
    Khan MS; Barratt DT; Somogyi AA
    Xenobiotica; 2016; 46(3):278-87. PubMed ID: 26161459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia.
    Wang Q; Jiang ZP; Zeng J; Zhu Y; Cai HL; Xiang DX; He Q; Shi XL; Zhong AN; Zhao XL; Xu P
    J Pharm Pharm Sci; 2020; 23(1):1-9. PubMed ID: 32027818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.
    Bouchet S; Poulette S; Titier K; Moore N; Lassalle R; Abouelfath A; Italiano A; Chevreau C; Bompas E; Collard O; Duffaud F; Rios M; Cupissol D; Adenis A; Ray-Coquard I; Bouché O; Le Cesne A; Bui B; Blay JY; Molimard M
    Eur J Cancer; 2016 Apr; 57():31-8. PubMed ID: 26851399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
    Teng JF; Mabasa VH; Ensom MH
    Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.
    Gómez-Sámano MÁ; Baquerizo-Burgos JE; Coronel MFC; Wong-Campoverde BD; Villanueva-Martinez F; Molina-Botello D; Avila-Rojo JA; Palacios-Báez L; Cuevas-Ramos D; Gomez-Perez FJ; Zentella-Dehesa A; Aguayo-González Á; Gulias-Herrero A
    BMC Endocr Disord; 2018 Nov; 18(1):77. PubMed ID: 30390651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.
    Osorio S; Escudero-Vilaplana V; Gómez-Centurión I; González-Arias E; García-González X; Díez JL
    J Oncol Pharm Pract; 2019 Apr; 25(3):694-698. PubMed ID: 29199506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
    Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
    J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
    Bedewy AM; El-Maghraby SM
    Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.